Semaglutide is a GLP-1 receptor agonist licensed for type 2 diabetes and weight management in the UK No direct mechanism exists linking semaglutide to reduced oestrogen production at the ovarian level Weight loss decreases adipose tissue containing aromatase enzyme, potentially reducing peripheral oestrogen conversion, particularly in postmenopausal women Semaglutide does not affect oral contraceptive efficacy and should be discontinued at least two months before planned pregnancy Women experiencing menstrual irregularities or severe menopausal symptoms during treatment should seek medical advice for appropriate investigation Table of Contents Understanding Ozempic and Hormonal Effects Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, at higher doses under the brand name Wegovy, for weight management in adults with obesity or overweight with weight-related comorbidities

When antibiotics, particularly Sulphur drugs, are used for extended periods, the normal synthesis of Folic acid in the gut will be reduced, and the requirement for Folic Acid are increased
"Clinically studied" on a label may refer to studies on the individual strains, not the specific product or combination
Your clinician will typically start by checking your health history
What are the risks of BPC-157
Programmed cell death in plants: a pathogen-triggered response activated coordinately with multiple defense functions